In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, discuss the evolving safety considerations and future directions of HER2-targeted antibody–drug conjugates (ADCs) across genitourinary, gastrointestinal, and gynecologic cancers. Toxicity Profiles of HER2-Targeted ADCs: Common and serious adverse events such as ILD/pneumonitis, neuropathy, and cytopenia across ADCs On-Target vs Off-Target Effects: How linker design, payload type, and drug-to-antibody ratio (DAR) contribute to toxicity Combination Therapy Considerations: Challenges in combining ADCs with immunotherapy or chemotherapy due to overlapping toxicities and tolerability concerns Presenters: Catherine Fahey, MD, PhD Assistant Professor Division of Oncology University of North Carolina at Chapel Hill Chapel Hill, North Carolina Alexandra Leary, MD, PhD President, GINECO Group Co-Director, Department of Medical Oncology Medical Oncologist Gynecology Team Leader, Gynecologic Translational Research Lab, INSERM u981 Institut Gustave Roussy Villejuif, France Funda Meric-Bernstam, MD Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy Nellie B. Connally Chair in Breast Cancer The University of Texas MD Anderson Cancer Center Houston, Texas Zev A. Wainberg, MD Professor of Medicine and Surgery Co-Director of GI Oncology Director, Early Phase Clinical Research Program Jonsson Comprehensive Cancer Center UCLA School of Medicine Los Angeles, California Link to full program: https://bit.ly/42iEDjV To claim credit for listening to this episode, please visit the podcast online at the link above. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
